Compound class:
Antibody
Comment: HLX22 is a humanized anti-HER2 (EGFR2; ERBB2) IgG1 monoclonal antibody. It binds within the same HER2 subdomain as trastuzumab, but at a separate, non-overlapping epitope [1]. HLX22 is proposed to offer synergistic antitumour efficacy in combination with trastuzumab/trastuzumab biosimilars.
|